Holen Sie sich die Stockscreener-App
23.02
1.96%
-0.46
Handel nachbörslich:
19.37
-3.65
-15.86%
Schlusskurs vom Vortag:
$23.48
Offen:
$22.3
24-Stunden-Volumen:
40.36M
Relative Volume:
2.04
Marktkapitalisierung:
$5.24B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
33.36
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-15.02%
1M Leistung:
-35.08%
6M Leistung:
-54.98%
1J Leistung:
-43.12%
1-Tages-Spanne:
$21.12
$23.62
1-Wochen-Bereich:
$21.12
$27.77
52-Wochen-Spanne:
$21.12
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
23.02 | 5.35B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.89 | 56.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
127.42 | 55.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.98 | 48.36B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.69 | 40.01B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.36 | 20.62B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash - BioPharma Dive
Hims & Hers removes a knock-off weight loss drug days after introducing it - Business Insider
Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill - Ottumwa Courier
HIMS Halts Compounded Weight-Loss Pill Amid Regulatory Pressure - GuruFocus
Hims & Hers Halts Sales of Wegovy Drug Amid FDA Pressure - intellectia.ai
Hims to stop offering GLP-1 pill after FDA warned of crackdown - KSL.com
Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny - Barron's
Hims & Hers abandons copycat weight-loss drug in face of FDA probe - Financial Times
Hims & Hers Scraps Copycat Wegovy Weight-Loss Pill After Probe - Bloomberg.com
Hims & Hers to stop offering copies of Novo Nordisk's new Wegovy pill - marketscreener.com
Hims & Hers to Stop Offering Compounded Semaglutide Pill After FDA Crackdown - US News Money
Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown - marketscreener.com
Hims & Hers Health Inc says we have decided to stop offering access to compounded semaglutide pill - marketscreener.com
Hims & Hers Health Inc Says We Have Decided To Stop Offering Access To Compounded Semaglutide Pill - TradingView
Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version - The Wall Street Journal
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action - AOL.com
HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch - Stocktwits
Weight-loss drugs to dominate Super Bowl advertising - Reuters Connect
HIMS Stock Slumps After-Hours On FDA Crackdown, Regulatory Scrutiny Over Compounded Wegovy Pill Launch - Stocktwits
Hims & Hers Stock Pre-Market (-16%): FDA Crackdown on New Weight-Loss Pill - Trefis
AI for investors - MLQ.ai
The healthcare companies advertising in Super Bowl LX - Modern Healthcare News
Hims & Hers Stock Pre-Market (-16%) : DOJ Probe & FDA Crackdown on Weight-Loss Drugs - Trefis
HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight - Law360
Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges. - Barron's
US announces crackdown on copycat weight-loss drugs - Financial Times
FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals (HIMS) - Bloomberg.com
US signals crackdown on compounded weight-loss drugs; Hims shares tumble - marketscreener.com
Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department - The Wall Street Journal
FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs - The Wall Street Journal
HIMSS Health Faces DOJ Investigation for Potential Legal Violati - GuruFocus
HIMS Shares Decline 13% After Market Hours - GuruFocus
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut - MarketBeat
Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. - Barron's
Hims & Hers Health says co looks forward to continuing to engage with FDA to ensure safe access to affordable healthcare - marketscreener.com
FDA to restrict GLP-1 ingredients used in non‑approved compounded drugs - Yahoo Finance
FDA scrutiny rattles Hims & Hers stock By Investing.com - Investing.com Nigeria
FDA scrutiny rattles Hims & Hers stock - Investing.com
FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation - Sherwood News
HHS general counsel Mike Stuart says based on review of applicable facts, referred Hims to DOJ for investigation for potential violations - marketscreener.com
HHS General Counsel refers Hims to US Justice Department for investigation - marketscreener.com
Compounded Semaglutide Pill From Hims & Hers Will Be Cheaper Than the Wegovy Pill — but Is It Just as Good? - everydayhealth.com
Hims in trouble, Novo says no-go as Trumprx.gov debuts - BioWorld MedTech
Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat - TechStock²
Hims & Hers stock closes at one-year low amid battle over compounded Wegovy pill - MarketWatch
GLP-1 manufacturers enter a turf war - Healthcare Brew
Hims And Hers Weight Loss Bet Faces GLP 1 Legal And FDA Tests - Yahoo Finance
The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market - FinancialContent
What's Going On With Novo Nordisk Stock On Friday? - Benzinga
Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market - Reuters
FDA warns against illegal copycat drugs, Molina stock sinks - Yahoo Finance
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):